![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
Showing 22 trials matching your filters.
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Und... Ruxolitinib in Thrombocythemia and Polycythemia Vera A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythe... Study of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera My... Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced My... Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syn... Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase M... Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis Study of Canakinumab in Patients With Myelofibrosis Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythe... Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Ph... Study to Assess SLN124 in Patients With Polycythemia Vera INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Ane... A Safety and Tolerability Study of Jaktinib Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Sign... An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms Reparixin in Patients with Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 12... KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relap... A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therap...
DRUG: Fludarabine
RADIATION: Total-Body Irradiation
PROCEDURE: Donor Lymphocyte Infusion
DRUG: Cyclophosphamide
DRUG: Tacrolimus
DRUG: Mycophenolate Mofetil
PROCEDURE: Hematopoietic Cell Transplantation
DRUG: Melphalan
PROCEDURE: Bone Marrow Aspiration and Biopsy
PROCEDURE: Diagnostic Imaging
PROCEDURE: Biospecimen Collection
This research is being done to see if the drug ruxolitinib is effective in reducing the symptoms caused by low-risk essential thrombocythemia (ET) and polycythemia vera (PV).
- This research study involves the study drug Ruxolitinib.
DRUG: Ruxolitinib
The main purpose of this study is to evaluate the efficacy of sapablursen in reducing the frequency of phlebotomy and in improving quality of life assessments in participants with polycythemia vera.
DRUG: sapablursen
This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.
DRUG: DISC-0974
AJX-101 is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK), clinical activity and changes in biomarkers of an orally administered type II...
DRUG: AJ1-11095
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis (MF) and other myeloid neoplasms.
DRUG: INCB057643
DRUG: Ruxolitinib
This is a prospective phase I dose-escalation study, with the primary objective to access the MTD and find the RP2D of talazoparib, given in combination with standard of care dosing of pacritinib.
DRUG: Talazoparib
DRUG: pacritinib
This phase II trial studies how well ruxolitinib phosphate and azacytidine work in treating patients with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm. Ruxolitinib phosphate may stop the growth of cancer cells by blocking som...
DRUG: Azacitidine
OTHER: Laboratory Biomarker Analysis
DRUG: Ruxolitinib Phosphate
This phase II trial studies how well decitabine with ruxolitinib, fedratinib, or pacritinib works before hematopoietic stem cell transplant in treating patients with accelerated/blast phase myeloproliferative neoplasms (tumors). Drugs used in chemoth...
DRUG: Decitabine
DRUG: Ruxolitinib
DRUG: Fedratinib
OTHER: Questionnaire Administration
DRUG: Pacritinib
This study evaluates either KRT-232 or TL-895 in treatment naïve patients with myelofibrosis (MF)
The study will be conducted in 2 stages. Stage 1 will evaluate safety, tolerability, and efficacy of either KRT-232 (Arm 1) or TL-895 (Arm 2) in treatm...
DRUG: KRT-232
DRUG: TL-895
This is an open label, multicenter, phase 2 trial of Canakinumab in patients with primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF). Eligible patients will receive Canakinumab administered as a s...
DRUG: Canakinumab
To learn if tasquinimod either alone or in combination with ruxolitinib can help to control PMF, post-PV MF, or post-ET MF.
DRUG: Ruxolitinib
DRUG: Tasquinimod
This phase I/II trial studies the best dose of ruxolitinib when given together with CPX-351 and to see how well they work in treating patients with accelerated phase or blast phase myeloproliferative neoplasm. Ruxolitinib may stop the growth of cance...
PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation
DRUG: Liposome-encapsulated Daunorubicin-Cytarabine
DRUG: Ruxolitinib
This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, pharmac...
DRUG: SLN124
DRUG: Placebo
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependen...
DRUG: INCB000928
DRUG: ruxolitinib
This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.
DRUG: Jaktinib Hydrochloride Tablet
The goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in Jak2V617F-positive high risk polycythemia vera patients.
DRUG: Givinostat
DRUG: Hydroxyurea
This phase II trial evaluates how a curcumin supplement (C3 complex/Bioperine) changes the inflammatory response and symptomatology in patients with clonal cytopenia of undetermined significance (CCUS), low risk myelodysplastic syndrome (LR-MDS), and...
PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Bone Marrow Biopsy
DIETARY_SUPPLEMENT: Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-containing Supplement
DIETARY_SUPPLEMENT: Piperine Extract (Standardized)
DRUG: Placebo Administration
OTHER: Questionnaire Administration
This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).
DRUG: N-Acetylcysteine
This is an open label, phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/...
DRUG: reparixin
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF.
Th...
DRUG: KRT-232
DRUG: Best Available Therapy (BAT)
The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use i...
DRUG: Bomedemstat
Get the latest thought leadership on your Polycythemia Vera delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.
HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.
Copyright © 2024 HealthTree Foundation. All rights reserved.
Tax ID 45-5354811